Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection

被引:17
|
作者
Axelrad, Jordan E. [1 ]
Li, Terry [2 ]
Bachour, Salam P. [3 ]
Nakamura, Takahiro, I [4 ]
Shah, Ravi [3 ]
Sachs, Michael C. [5 ]
Chang, Shannon [1 ]
Hudesman, David P. [1 ]
Holubar, Stefan D. [6 ]
Lightner, Amy L. [6 ]
Barnes, Edward L. [7 ]
Cohen, Benjamin L. [8 ]
Rieder, Florian [8 ]
Esen, Eren [9 ]
Remzi, Feza [9 ]
Regueiro, Miguel [8 ]
Click, Benjamin [8 ]
机构
[1] NYU, Dept Med, Divison Gastroenterol, Grossman Sch Med, New York, NY 10016 USA
[2] NYU, Dept Med, Grossman Sch Med, New York, NY 10016 USA
[3] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA
[4] Univ Vermont, Dept Med, Divison Gastroenterol, Larner Coll Med, Burlington, VT USA
[5] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[6] Cleveland Clin, Dept Colorectal Surg, Cleveland, OH 44106 USA
[7] UNC Sch Med, Dept Med, Div Gastroenterol, Chapel Hill, NC USA
[8] Cleveland Clin, Dept Gastroenterol Hepatol & Nutr, Cleveland, OH 44106 USA
[9] NYU, Dept Surg, Grossman Sch Med, New York, NY 10016 USA
关键词
Crohn's disease; postoperative recurrence; resection; biologic therapy; MAGNETIC-RESONANCE ENTEROGRAPHY; COMPUTED-TOMOGRAPHY; ILEOCOLIC RESECTION; METAANALYSIS; ADALIMUMAB; RISK; PREVENTION; MANAGEMENT;
D O I
10.1093/ibd/izac158
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Lay Summary Postoperative recurrence of Crohn's disease is common after ileocecal resection. In this dual-center study, early initiation of an anti-TNF agent within 4 weeks following an ileocecal resection was associated with a reduction in postoperative recurrence of Crohn's disease. Background Postoperative recurrence (POR) of Crohn's disease (CD) is common after surgical resection. We aimed to compare biologic type and timing for preventing POR in adult CD patients after ileocecal resection (ICR). Methods We performed a retrospective cohort study of CD patients who underwent an ICR at 2 medical centers. Recurrence was defined by endoscopy (>= i2b Rutgeerts score) or radiography (active inflammation in neoterminal ileum) and stratified by type and timing of postoperative prophylactic biologic within 12 weeks following an ICR (none, tumor necrosis factor antagonists [anti-TNF], vedolizumab, and ustekinumab). Results We identified 1037 patients with CD who underwent an ICR. Of 278 (26%) who received postoperative prophylaxis, 80% were placed on an anti-TNF agent (n = 223) followed by ustekinumab (n = 28, 10%) and vedolizumab (n = 27, 10%). Prophylaxis was initiated in 35% within 4 weeks following an ICR and in 65% within 4 to 12 weeks. After adjusting for factors associated with POR, compared with no biologic prophylaxis, the initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR (adjusted hazard ratio, 0.61; 95% CI, 0.40-0.93). Prophylaxis after 4 weeks following an ICR or with vedolizumab or ustekinumab was not associated with a reduction in POR compared with those who did not receive prophylaxis. Conclusion Early initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR. Vedolizumab or ustekinumab, at any time following surgery, was not associated with a reduction in POR, although sample size was limited.
引用
收藏
页码:888 / 897
页数:10
相关论文
共 50 条
  • [31] Predictive value of tissue calprotectin for disease recurrence after ileocecal resection in pediatric Crohn's disease
    Zarubova, Kristyna
    Fabian, Ondrej
    Hradsky, Ondrej
    Lerchova, Tereza
    Mikus, Filip
    Dotlacil, Vojtech
    Pos, Lucie
    Skaba, Richard
    Bronsky, Jiri
    BIOMEDICAL PAPERS-OLOMOUC, 2022, 166 (03): : 297 - 303
  • [32] Risk Factors for Complications and Disease Recurrence after Ileocecal Resection for Crohn's Disease in Children and Adults
    Dipasquale, Valeria
    Milone, Erica
    Nigro, Stefania
    Alibrandi, Angela
    Antonelli, Enrica
    Di Fabrizio, Donatella
    Romeo, Carmelo
    Navarra, Giuseppe
    Romano, Claudio
    BIOMEDICINES, 2024, 12 (04)
  • [33] Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis
    Canete, Fiorella
    Manosa, Miriam
    Perez-Martinez, Isabel
    Barreiro-de Acosta, Manuel
    Gonzalez-Sueyro, Ramiro C.
    Nos, Pilar
    Iglesias-Flores, Eva
    Gutierrez, Ana
    Bujanda, Luis
    Gordillo, Jordi
    Leon, Raquel Rios
    Casanova, Maria Jose
    Villoria, Albert
    Rodriguez-Lago, Iago
    Serrano, Pilar Lopez
    Garcia-Herola, Antonio
    Ramirez-de La Piscina, Patricia
    Navarro-Llavat, Merce
    Taxonera, Carlos
    Barrio, Jesus
    Ramos, Laura
    Navarro, Pablo
    Benitez-Leiva, Olga
    Calafat, Margalida
    Domenech, Eugeni
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2020, 11
  • [34] Laparoscopic ileocecal resection in pediatric Crohn's disease: effect of anastomotic configuration on postoperative outcomes in the era of biologic therapy
    Dotlacil, V
    Lerchova, T.
    Kucerova, B.
    Schwarz, J.
    Hradsky, O.
    Skaba, R.
    Rygl, M.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1838 - I1838
  • [35] Inflammatory Cytokine Profile in Crohn's Disease Nonresponders to Optimal Antitumor Necrosis Factor Therapy
    Yarur, Andres J.
    Jain, Anjali
    Quintero, Maria A.
    Czul, Frank
    Deshpande, Amar R.
    Kerman, David H.
    Abreu, Maria T.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2019, 53 (03) : 210 - 215
  • [36] Mycobacterium marinum Infection in the Setting of Antitumor Necrosis Factor alpha Therapy for Crohn's Disease
    Levesque, Barrett G.
    Sandborn, William J.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 (06) : 1443 - 1444
  • [37] Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocecal resection for Crohn's disease: results from the MULTIPER database
    Kotze, P. G.
    Suzuki, Y.
    Yamamoto, T.
    Danese, S.
    Saad-Hossne, R.
    Teixeira, F.
    Albuquerque, I.
    Silva, R.
    Barcelos, I.
    Yamada, A.
    Kotze, L.
    Sacchi, M.
    Olandoski, M.
    Spinelli, A.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S284 - S284
  • [38] Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn's Disease Recurrence
    Yu, Jongwook
    Hyun, Hye Kyung
    Park, Jihye
    Kang, Eun Ae
    Park, Soo Jung
    Park, Jae Jun
    Kim, Tae Il
    Kim, Won Ho
    Cheon, Jae Hee
    GUT AND LIVER, 2022, 16 (03) : 414 - 422
  • [39] Does the Location of an IBD Centre Impact the Rates of Early Postoperative Endoscopic Recurrence After Ileocecal Resection in Crohn's Disease? Results From the Multiper Database
    Kotze, Paulo G.
    Yamamoto, Takayuki
    Danese, Silvio
    Suzuki, Yasuo
    Albuquerque, Idblan C.
    Barcelos, Ivan F.
    Kotze, Lorete M.
    Olandoski, Marcia
    Teixeira, Fabio V.
    Silva, Rodolff N.
    Sacchi, Matteo
    Yamada, Akihiro
    Saad-Hossne, Rogerio
    Spinelli, Antonino
    GASTROENTEROLOGY, 2014, 146 (05) : S451 - S452
  • [40] Direct Retrospective Comparison of Adalimumab and Infliximab in Preventing Early Postoperative Endoscopic Recurrence After Ileocecal Resection for Crohn's Disease: Results From the Multiper Database
    Kotze, Paulo G.
    Suzuki, Yasuo
    Yamamoto, Takayuki
    Danese, Silvio
    Saad-Hossne, Rogerio
    Albuquerque, Idblan C.
    Teixeira, Fabio V.
    Silva, Rodolff N.
    Barcelos, Ivan F.
    Olandoski, Marcia
    Kotze, Lorete M.
    Yamada, Akihiro
    Spinelli, Antonino
    GASTROENTEROLOGY, 2014, 146 (05) : S451 - S451